Loading…
Based on limited metadata without access to the full letter text, the FDA issued a warning to Henan Lihua Pharmaceutical Co., Ltd., a pharmaceutical manufacturer, on June 12, 2018. The specific violations and their nature cannot be determined from the available metadata, as no subject line details are provided. Without the issuing office information or complete letter contents, the regulatory scope and product category requiring remediation cannot be definitively characterized. A review of the full warning letter would be necessary to identify the specific compliance issues and violations cited by the FDA.